The Primary Biliary Cirrhosis Market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.5 billion by 2034, registering a CAGR of 7.5%. This growth trajectory is underpinned by several key factors, including the rising prevalence of autoimmune diseases, advancements in diagnostic technologies, and an increasing focus on personalized medicine. The demand for effective treatment...

Primary Biliary Cirrhosis, now more commonly referred to as Primary Biliary Cholangitis (PBC), is a chronic autoimmune liver disease characterized by the progressive destruction of the small bile ducts within the liver. This destruction leads to bile stasis (cholestasis), which causes liver tissue damage, scarring (fibrosis), and eventually cirrhosis or liver failure. The market focuses on...

"Future of Executive Summary Primary Biliary Cirrhosis Market: Size and Share Dynamics Data Bridge Market Research analyses a growth rate in the global primary biliary cirrhosis market in the forecast period 2022-2029.  The Primary Biliary Cirrhosis business document lists and studies the leading competitors and also provides the insights with strategic industry analysis of the key factors...